Eisai: Biogen Documents New Drug Application for Aducanumab in Japan

– If accredited, aducanumab would turn into the to start with procedure to meaningfully modify the study course of Alzheimer’s ailment
– Aducanumab is now under regulatory assessment in Japan, Europe and the United States

TOKYO, Dec 11, 2020 – (JCN Newswire) – Biogen and Eisai, Co., Ltd. (Tokyo, Japan) introduced that Biogen has submitted a Japanese New Drug Software (J-NDA) to the Ministry of Overall health, Labor and Welfare (MHLW) for aducanumab, an investigational therapy for Alzheimer’s sickness. Aducanumab, an amyloid beta-concentrating on antibody, has been revealed in clinical trials to take away amyloid beta in the mind and substantially gradual clinical decline in patients with Gentle Cognitive Impairment (MCI) thanks to Alzheimer’s disorder and mild Alzheimer’s ailment dementia.

“Japan is the 3rd market in which we have applied for regulatory approval for aducanumab, and the submitting signifies continued development on our motivation to carry this remedy to clients